![If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach](https://www.gkseries.com/blog/wp-content/uploads/2022/01/If-a-patient-of-advanced-NSCLC-no-targetable-driver-mutation-is-found-and-PD-L1-expression-is-≥-50-which-of-the-following-will-be-the-best-treatment-approach.png)
Q. If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach :
A. Pembrolizumab
B. Pembrolizumab plus single agent platinum
C. Pembrolizumab plus platinum based doublet chemotherapy
D. Platinum based doublet chemotherapy
Answer: Pembrolizumab